HH2853 Tablets

DRUG2 trials

Sponsors

Haihe Biopharma Co., Ltd.

Conditions

Advanced Solid TumorEpithelioid SarcomaFL LymphomaPeripheral T Cell LymphomaRelapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

Phase 1

Evaluate the Safety and Clinical Activity of HH2853

RecruitingNCT04390737

Haihe Biopharma Co., Ltd.Advanced Solid Tumor, Epithelioid Sarcoma, FL Lymphoma +1

Start: 2020-09-08End: 2028-12-31Target: 254Updated: 2026-01-30

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

RecruitingNCT06909877

Haihe Biopharma Co., Ltd.Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

Start: 2022-07-27End: 2027-07-30Target: 100Updated: 2026-01-30

Related Papers

Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study.

2025-08-07

A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma

Journal of Hematology & Oncology2025-04-271 citations

HH2853, an EZH1/2 inhibitor, in patients with epithelioid sarcoma: Preliminary results from the phase 1 part of a first-in-human phase I/II study.

Journal of Clinical Oncology2023-06-012 citations

Abstract CT105: Preliminary results from the Phase I part of a first-in-human Phase I/II study of HH2853, an EZH1/2 inhibitor, in patients with relapsed/refractory non-Hodgkin lymphomas or advanced solid tumors

Cancer Research2023-04-141 citations